At SEB's Nordic Seminar, FluoGuide CEO Morten Albrechtsen clearly laid out the equity story and discussed the path to approval and reimbursement. We were particularly interested in his thoughts about the need for flexibility in the clinical programme to be able to demonstrate clinical efficacy, superiority, and methods of use, in order to maximise reimbursement. We were also encouraged that FluoGuide's clinical program continues to be on track.

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.